Mirum Pharmaceuticals, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Mirum Pharmaceuticals, Inc. (MIRM) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $4.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Mirum Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $4.47M.
- Mirum Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $771.00K.
- Mirum Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Mirum Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $2.44M, a 74.63% decline from fiscal 2024.
- Mirum Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $9.63M, a 1936.58% increase from fiscal 2023.
- Mirum Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $473.00K, a 65.96% increase from fiscal 2022.
- Mirum Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $285.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 8 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.47M 10-Q · filed 2026-08-05 | $5.24M derived: sum of 3 quarters · filed 2026-08-05 | $5.24M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $4.47M 10-Q · filed 2026-05-06 | $5.24M derived: sum of 2 quarters · filed 2026-05-06 | $5.24M derived: sum of 3 quarters · filed 2026-05-06 | $6.92M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $771.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $771.00K derived: sum of 2 quarters · filed 2026-02-25 | $2.44M derived: sum of 3 quarters · filed 2026-08-05 | $2.44M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.67M derived: sum of 2 quarters · filed 2026-08-05 | $1.67M 10-Q · filed 2025-11-04 | $1.67M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.67M 10-Q · filed 2026-08-05 | $1.67M derived: sum of 3 quarters · filed 2026-08-05 | $2.41M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $737.00K derived: sum of 3 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $737.00K derived: sum of 2 quarters · filed 2026-02-25 | $9.63M 10-K · filed 2026-02-25 | ||
| 2024-09-30 | $737.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $9.63M 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | $8.90M 10-Q · filed 2025-08-06 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $473.00K 10-K · filed 2026-02-25 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $473.00K 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | $473.00K 10-Q · filed 2024-08-07 | ||||
| 2022-12-31 | $285.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $285.00K derived: sum of 2 quarters · filed 2025-02-26 | $285.00K 10-K · filed 2025-02-26 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-07 | ||||
| 2021-12-31 | $0.00 10-K · filed 2024-03-15 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $0.00 derived: sum of 2 quarters · filed 2021-03-09 | $0.00 derived: sum of 3 quarters · filed 2021-03-09 | $0.00 10-K · filed 2021-03-09 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 derived: sum of 2 quarters · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | $2.26M derived: sum of 4 quarters · filed 2021-03-09 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $2.26M derived: sum of 3 quarters · filed 2021-03-09 | $2.28M derived: sum of 4 quarters · filed 2021-03-09 | |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 | $2.26M derived: sum of 2 quarters · filed 2021-03-09 | $2.28M derived: sum of 3 quarters · filed 2021-03-09 | $2.43M derived: sum of 4 quarters · filed 2021-03-09 | |
| 2019-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $2.28M derived: sum of 2 quarters · filed 2021-03-09 | $2.43M derived: sum of 3 quarters · filed 2021-03-09 | $3.70M 10-K · filed 2021-03-09 | |
| 2019-09-30 | $26.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $176.00K derived: sum of 2 quarters · filed 2020-11-12 | $1.44M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $150.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $1.42M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $1.27M 10-Q · filed 2020-05-07 | ||||
| 2018-12-31 | $0.00 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |